Friday, 22 October 2021

 

 

LATEST NEWS Make All Efforts For Instilling Confidence Of General Public In Law And Order Machinery- Cm To Punjab Police Youth To Be Deciding Factor In Vidhan Sabha Polls : Charanjit Singh Channi Massive protest against Cong MLA Joginderpal at Pathankot Police Commemoration Day observed at DPL Pulwama Intense Dengue control measures afoot Punjab Government To Come Up With A Roadmap To Revamp Education System : Pargat Singh The public knows who did corruption and who went to the court for the same : Vinod Thakur Central University of Punjab organized an Invited lecture on “Universal Human Values” Raja Warring's report card does not include any action against political transport mafia : Dinesh Chadha Tamannah Bhatia among top 10 most influential social media stars in south Being Punjabi an advantage in portraying a 'Sardar' : Pawan Malhotra Debina Bonnerjee's prosthetics for 'Shubho Bijoya' will leave you in shock Government recognizes Purzgars as vital pillar in Shawl Industry Police Martyrs Day observed at DPL Ganderbal, Pulwama Director Agriculture Kashmir inaugurates sale of Vegetable seedlings at Kitchen Garden, Lal Mandi Snow forecast : DC Bandipora reviews winter preparedness Disst. Adm. Kupwara organizes 4 block diwas programmes at Hayhama, Langate, Kalaroos, Tad Sonamarg to be promoted as all season tourist destination : Pandurang Kondbara Pole Charanjit Singh Channi Reviews Preparedness For Progressive Punjab Investors Summit We Should Fight Anti-National Forces Jointly : Gurpreet Singh Bhullar Commissionerate Police Give Rousing Welcome To Motorcycle Rally On Its Arrival At Jalandhar To Mark National Unity Day

 

Sanofi-GSK Covid vax shows strong immune responses in Phase 2 trial

Coronavirus, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Covid-19 Vaccine, Oxygen, #OxygenCylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Covifor, Oxygen supply, Liquid Medical Oxygen, Sanofi and Glaxo Smith Kline, GSK, Sanofi-GSK Covid vax

Web Admin

Web Admin

5 Dariya News

Paris , 18 May 2021

A Covid-19 vaccine developed by pharmaceutical giants Sanofi and Glaxo Smith Kline (GSK) has shown strong rates of neutralising antibody responses against the infectious Coronavirus disease in the Phase-II trial.The Phase-II trial, which involved 722 adult volunteers from the US and Honduras between 18 to 95 years old, did not raise any safety concerns and also produced a strong immune response across all age groups.It showed 95 per cent to 100 per cent seroconversion following a second injection, while a single jab produced high neutralising antibody levels among people with prior SARS-CoV-2 infection. This suggested the vaccine's strong potential for development as a booster shot.The vaccine also elicited strong neutralising antibody levels that were comparable to those generated by natural infection. The higher levels observed in people between 18 to 59 years old."Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases," said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, in a statement."These positive data show the potential of this protein-based adjuvanted vaccine candidate in the broader context of the pandemic, including the need to address variants and to provide for booster doses. We believe that this vaccine candidate can make a significant contribution to the ongoing fight against Covid-19," added Roger Connor, President of GSK Vaccines.In December, last year, the Sanofi-GSK faced a major setback after their experimental Covid-19 vaccine did not appear to work well in older adults.The pharma companies, now, aim to start a global pivotal Phase 3 study in the coming weeks. The Phase-III trial is expected to enroll more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B1351 (South African) variants.The French pharma company Sanofi and its British peer GSK aim to produce up to one billion doses in 2021.In addition, the companies also intend to conduct booster studies with various variant formulations in order to assess the ability of a lower dose of the vaccine to generate a strong booster response regardless of the initial vaccine platform received.

 

Tags: Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Covid-19 Vaccine , Oxygen , #OxygenCylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Covifor , Oxygen supply , Liquid Medical Oxygen , Sanofi and Glaxo Smith Kline , GSK , Sanofi-GSK Covid vax

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD